OREXO AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.15 USD | +7.50% |
|
+7.50% | +42.38% |
| May. 08 | Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024 | |
| May. 08 | Orexo AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +42.38% | 69.4M | - | ||
| +4.96% | 70.02B | A | ||
| +16.65% | 9.05B | A- | ||
| -22.81% | 4.43B | A- | ||
| +14.83% | 4.16B | B- | ||
| +19.21% | 3.83B | - | ||
| -1.86% | 2.06B | B | ||
| +8.78% | 2.02B | - | - | |
| -36.94% | 1.9B | C- | ||
| -45.25% | 1.71B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ORX Stock
- ORXOY Stock
- Ratings Orexo AB
